Myles Minter

Stock Analyst at William Blair

(2.41)
# 2,421
Out of 5,179 analysts
25
Total ratings
52.63%
Success rate
10.55%
Average return

Stocks Rated by Myles Minter

Korro Bio
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $10.40
Upside: -
Neumora Therapeutics
Feb 17, 2026
Upgrades: Outperform
Price Target: n/a
Current: $2.33
Upside: -
Biohaven
Nov 5, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $8.37
Upside: -
Alector
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.00
Upside: -
Dianthus Therapeutics
Jul 2, 2025
Initiates: Outperform
Price Target: n/a
Current: $81.13
Upside: -
Immunic
Mar 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $1.09
Upside: -
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.31
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $691.40
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $6.76
Upside: +950.30%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $49.56
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $433.07
Upside: -
Downgrades: Market Perform
Price Target: n/a
Current: $290.10
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $4.62
Upside: -
Initiates: Outperform
Price Target: n/a
Current: $317.36
Upside: -
Upgrades: Outperform
Price Target: n/a
Current: $72.15
Upside: -
Initiates: Outperform
Price Target: $116
Current: $128.32
Upside: -9.60%